论文部分内容阅读
目的：观察ＮＰＣ放疗中配合用ＣＤ３ＡＫ细胞治疗的效果。方法：将ＮＰＣ分两组：Ａ组７２例（放疗＋ＣＤ３ＡＫ细胞治疗），Ｂ组９７例（单纯放疗）。治疗前后分别记录肿瘤情况，急性放射反应，Ｋａｒｎｏｆｓｋｙ氏评分，并检测外周血Ｔ淋巴细胞亚群和血清ＥＢ－ＶＣＡ－ＩｇＡ抗体水平。结果：①Ａ、Ｂ二组肿瘤消除率分别是９１．６７％、８７．６３％，ＥＢ－ＶＣＡ－ＩｇＡ降低者分别占７８％、６９％。Ａ、Ｂ组两项指标比较均无显著性差异（Ｐ＞０．０５）；②急性放射反应Ａ组明显比Ｂ组轻（Ｐ＜０．０１），Ｋａｒｎｏｆｓｋｙ氏评分Ａ组比Ｂ组有所改善（Ｐ＜０．０５）；③免疫指标：Ａ组的ＣＤ＋８比值下降，ＣＤ＋３、ＣＤ＋４、ＣＤ＋４／ＣＤ＋８比值均明显升高，而Ｂ组变化不大。结论：ＣＤ３ＡＫ细胞配合放疗治疗ＮＰＣ安全可靠，与放疗有相加（协同）作用，可明显减轻急性放射反应，并有提高患者免疫功能的作用。
Objective: To observe the effect of combined use of CD3AK cells in NPC radiotherapy. Methods: The NPCs were divided into two groups: 72 patients in group A (radiotherapy plus CD3AK cell therapy) and 97 patients in group B (radiotherapy alone). The tumor status, acute radiation reaction, Karnofsky’s score were recorded before and after treatment, and the peripheral blood T-lymphocyte subsets and serum EB-VCA-IgA antibody levels were measured. RESULTS: The elimination rates of tumors in groups 1A and B were 91.67% and 87.63%, respectively, and those with decreased EB-VCA-IgA accounted for 78% and 69%, respectively. There was no significant difference between the two indexes in group A and B (P>0.05); 2 Acute radiation reaction was significantly lighter in group A than in group B (P<0.01). Karnofsky’s score in group A was more than that in group B. Improvement (P<0.05); 3Immunity index: The ratio of CD+8 in group A decreased, and the ratios of CD+3, CD+4, and CD+4/CD+8 increased significantly. However, there was no significant change in group B. Conclusion: CD3AK cells combined with radiotherapy for NPC are safe and reliable, and have additive (synergistic) effects with radiotherapy, which can significantly reduce acute radiation reactions and improve the immune function of patients.